Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human...
Pharmaceutical
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and...
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at...
Applied Therapeutics Reports Second Quarter 2023 Financial Results
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the...
Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million
Fiscal Q1 2024 revenue reflects a 37% increase over fiscal Q1 2023, demonstrating strong revenue growth and continued overall performanceManagement...
Pressure BioSciences Reports Strongly Accelerating UltraShear Nano-CBD Orders
Since Mid-July Launch into Aggressive Expansion Phase, Company Adds Five New U.S. Distributors and Secures Initial Market-Seeding Orders for Over...
MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast
PHOENIX, AZ / ACCESSWIRE / August 9, 2023 / The Stock Day Podcast welcomed MIRA Pharmaceuticals, Inc.(Nasdaq:MIRA) ("the Company"), a...
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates
Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024...
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in...
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry AdoptionWith Partnership, Ainos Makes Progress Towards...
Protagonist Receives $34 Million from Warrant Exercises
Estimated cash runway now extended through Q1 2026NEWARK, CA / ACCESSWIRE / August 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist"...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
Financials for First Quarter Fiscal Year 2024 Ended June 30, 2023 will be released on August 14, 2023NORTHVALE, NJ /...
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) (“RespireRx”), focused on the...
TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023
Company to hold conference call and webcast on August 15, 2023, at 11:00 AM ETFORT WORTH, Texas, Aug. 09, 2023...
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Bioz Inc. Has Partnered With Avanti Polar Lipids to Bring Evidence-Based Recommendations to Scientists
PALO ALTO, CA / ACCESSWIRE / August 9, 2023 / Bioz, Inc., a leading AI software company based in Silicon...
AlzeCure Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer’s
STOCKHOLM, SWEDEN / ACCESSWIRE / August 9, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Model N Announces Third Quarter Fiscal Year 2023 Financial Results
Total Revenue Grew 13% Year-over-Year SaaS ARR Grew 28% Year-over-YearSAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / August...
Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity
New Branding Reflects Company's Commitment to the Future of WellnessSHERMAN OAKS, CA / ACCESSWIRE / August 8, 2023 / Avenir...